PE20250785A1 - SOLUCIONES FARMACEUTICAS DE ANTICUERPOS ANTI-N3PGLU Aß Y USOS DE ESTAS - Google Patents
SOLUCIONES FARMACEUTICAS DE ANTICUERPOS ANTI-N3PGLU Aß Y USOS DE ESTASInfo
- Publication number
- PE20250785A1 PE20250785A1 PE2025000205A PE2025000205A PE20250785A1 PE 20250785 A1 PE20250785 A1 PE 20250785A1 PE 2025000205 A PE2025000205 A PE 2025000205A PE 2025000205 A PE2025000205 A PE 2025000205A PE 20250785 A1 PE20250785 A1 PE 20250785A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- n3pglu
- pharmaceutical solutions
- pharmaceutical
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se relaciona con soluciones farmaceuticas de ciertos anticuerpos anti-N3pGlu ABeta. Tambien se describen usos de tales soluciones farmaceuticas, que incluyen el uso en el tratamiento de la enfermedad de Alzheimer. Se trata de una solucion farmaceutica que comprende un anticuerpo anti-N3pGlu ABeta que comprende (a) una region variable de cadena ligera (LCVR) que comprende una LCDR1 de la sec. con num. de ident.: 5, una LCDR2 de la sec. con num. de ident.: 6, y una LCDR3 de la sec. con num. de ident.: 7, y (b) una region variable de cadena pesada (HCVR) que comprende una HCDR1 de la sec. con num. de ident.: 8, una HCDR2 de la sec. con num. de ident.: 9, y una HCDR3 de la sec. con num. de ident.: 10, un regulador, un agente de tonicidad, un surfactante, y un excipiente opcional; en cantidades que son suficientes en combinacion para una solucion farmaceutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263369033P | 2022-07-21 | 2022-07-21 | |
| PCT/US2023/070540 WO2024020470A1 (en) | 2022-07-21 | 2023-07-20 | PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250785A1 true PE20250785A1 (es) | 2025-03-14 |
Family
ID=87576063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2025000205A PE20250785A1 (es) | 2022-07-21 | 2023-07-20 | SOLUCIONES FARMACEUTICAS DE ANTICUERPOS ANTI-N3PGLU Aß Y USOS DE ESTAS |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4558166A1 (es) |
| JP (1) | JP2025525587A (es) |
| KR (1) | KR20250037554A (es) |
| CN (1) | CN119604302A (es) |
| AR (1) | AR129994A1 (es) |
| AU (1) | AU2023309007A1 (es) |
| CA (1) | CA3261418A1 (es) |
| CL (1) | CL2025000145A1 (es) |
| CO (1) | CO2025000508A2 (es) |
| CR (1) | CR20250023A (es) |
| DO (1) | DOP2025000005A (es) |
| IL (1) | IL318102A (es) |
| MA (1) | MA71558A (es) |
| MX (1) | MX2025000820A (es) |
| PE (1) | PE20250785A1 (es) |
| TW (1) | TW202421188A (es) |
| WO (1) | WO2024020470A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3042917T (lt) * | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
-
2023
- 2023-07-20 CR CR20250023A patent/CR20250023A/es unknown
- 2023-07-20 WO PCT/US2023/070540 patent/WO2024020470A1/en not_active Ceased
- 2023-07-20 JP JP2025502865A patent/JP2025525587A/ja active Pending
- 2023-07-20 CN CN202380055471.XA patent/CN119604302A/zh active Pending
- 2023-07-20 MA MA71558A patent/MA71558A/fr unknown
- 2023-07-20 AU AU2023309007A patent/AU2023309007A1/en active Pending
- 2023-07-20 KR KR1020257005184A patent/KR20250037554A/ko active Pending
- 2023-07-20 IL IL318102A patent/IL318102A/en unknown
- 2023-07-20 PE PE2025000205A patent/PE20250785A1/es unknown
- 2023-07-20 EP EP23755273.2A patent/EP4558166A1/en active Pending
- 2023-07-20 CA CA3261418A patent/CA3261418A1/en active Pending
- 2023-07-21 AR ARP230101919A patent/AR129994A1/es unknown
- 2023-07-21 TW TW112127310A patent/TW202421188A/zh unknown
-
2025
- 2025-01-16 CL CL2025000145A patent/CL2025000145A1/es unknown
- 2025-01-17 CO CONC2025/0000508A patent/CO2025000508A2/es unknown
- 2025-01-20 DO DO2025000005A patent/DOP2025000005A/es unknown
- 2025-01-20 MX MX2025000820A patent/MX2025000820A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA71558A (fr) | 2025-05-30 |
| IL318102A (en) | 2025-02-01 |
| CR20250023A (es) | 2025-02-17 |
| CN119604302A (zh) | 2025-03-11 |
| CL2025000145A1 (es) | 2025-05-30 |
| MX2025000820A (es) | 2025-03-07 |
| JP2025525587A (ja) | 2025-08-05 |
| EP4558166A1 (en) | 2025-05-28 |
| CA3261418A1 (en) | 2024-01-25 |
| WO2024020470A1 (en) | 2024-01-25 |
| TW202421188A (zh) | 2024-06-01 |
| CO2025000508A2 (es) | 2025-02-04 |
| AR129994A1 (es) | 2024-10-23 |
| KR20250037554A (ko) | 2025-03-17 |
| AU2023309007A1 (en) | 2025-01-30 |
| DOP2025000005A (es) | 2025-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| ES2564252T3 (es) | Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| ES2656000T3 (es) | Anticuerpos frente a CGRP | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20091205A1 (es) | Anticuerpo anti-receptor de il-6 | |
| PE20080119A1 (es) | Anticuerpos anti-5ta y sus usos | |
| PE20191045A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
| RU2015110981A (ru) | Комбинации и их применение | |
| PE20201494A1 (es) | Anticuerpo anti-pacap | |
| AR125212A1 (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas | |
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| PE20212185A1 (es) | Formulacion de anticuerpos terapeuticos | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| UY39878A (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma |